AR
ARTV.US Artiva Biotherapeutics, Inc. Common Stock
- Market cap
- USD 198M
- P/E
- -
- P/B
- 0.61x
- ROE
- -32.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ARTV.US undervalued?
Graham numberThe Graham number of Artiva Biotherapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Artiva Biotherapeutics, Inc. Common Stock fundamental analysis
No fundamental analysis for Artiva Biotherapeutics, Inc. Common Stock yet.
Artiva Biotherapeutics, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibo…
Full company profileArtiva Biotherapeutics, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Artiva Biotherapeutics, Inc. Common Stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 2.00M | 4.93M | 33.5M | 251K | 0.00 | 0.00 |
| Gross Profit | - | 2.00M | 4.93M | 33.5M | 251K | -2.60M | - |
| Operating Income | -18.3M | -53.3M | -59.8M | -30.7M | -67.3M | -90.6M | -111M |
| EBITDA | -17.5M | -71.6M | -57.2M | -25.4M | -56.1M | -81.3M | -100M |
| Net Income | -18.0M | -71.8M | -58.4M | -27.7M | -58.5M | -83.9M | -103M |
| EPS | -1.02 | -4.08 | -3.32 | -1.19 | -2.40 | -3.43 | -2.01 |
| Balance Sheet | |||||||
| Total Assets | 29.2M | 170M | 133M | 105M | 210M | 131M | 343M |
| Total Liabilities | 50.8M | 259M | 274M | 267M | 22.9M | 21.0M | 22.3M |
| Shareholders' Equity | -21.6M | -88.9M | -141M | -162M | 187M | 110M | 321M |
| Cash & Short-term Investments | 25.4M | 161M | 103M | 77.0M | 185M | 108M | 319M |
| Total Debt | 2.12M | 1.74M | 19.4M | 16.9M | 14.4M | 10.9M | 9.17M |
| Cash Flow | |||||||
| Operating Cash Flow | -13.5M | -15.3M | -50.8M | -47.4M | -55.0M | -76.8M | -121M |
| Capital Expenditure | 284K | 1.72M | 6.30M | 3.26M | 642K | 2.59M | 2.59M |
| Free Cash Flow | -13.8M | -17.0M | -57.1M | -50.7M | -55.7M | -79.3M | -124M |
| Ratios | |||||||
| ROE | - | - | - | - | -31.3% | -76.3% | -32.2% |
| ROA | -61.5% | -42.3% | -43.9% | -26.3% | -27.9% | -64.0% | -30.1% |
| Net Profit Margin | - | -3,587.7% | -1,184.1% | -82.7% | -23,304.0% | - | - |
| Debt to Equity | - | - | - | - | 0.08x | 0.10x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Artiva Biotherapeutics, Inc. Common Stock dividends
Artiva Biotherapeutics, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns Artiva Biotherapeutics, Inc. Common Stock
- Insiders 14.77%
- Institutions 83.54%
- Public & others 1.69%
- Shares outstanding 49.4M
- Free float 20.2M
Top funds holding ARTV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 940K | 1.92% | 0.00% | Sep 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 700K | 1.43% | 0.00% | Sep 2026 |
| Franklin Biotechnology Discovery A | 542K | 1.11% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 468K | 0.96% | 0.00% | Oct 2026 |
| Franklin Small Cap Growth Adv | 456K | 0.93% | 0.00% | Sep 2026 |
| iShares Russell 2000 Value ETF | 148K | 0.30% | 0.00% | Oct 2026 |
| Vanguard US Momentum Factor ETF | 126K | 0.26% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 112K | 0.23% | +322.81% | Sep 2026 |
| Fidelity Extended Market Index | 99.9K | 0.20% | -13.24% | Sep 2026 |
| iShares Micro-Cap ETF | 57.9K | 0.12% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 51.6K | 0.11% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 50.3K | 0.10% | -0.37% | Oct 2026 |
| Bridgeway Ultra-Small Company | 50.0K | 0.10% | 0.00% | Jun 2026 |
| A4Investments SICAV SIF ACCI IlanaA2EURH | 50.0K | 0.10% | 0.00% | Oct 2026 |
| Vifag 2002 SICAV | 50.0K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 49.7K | 0.10% | -0.05% | Sep 2026 |
| Schwab Small Cap Index | 47.0K | 0.10% | +308.34% | Sep 2026 |
| Franklin Small Cap Enhanced ETF | 44.2K | 0.09% | 0.00% | Oct 2026 |
| Bridge Builder Small Cap Fund | 43.5K | 0.09% | 0.00% | Oct 2026 |
| Fidelity Series Total Market Index | 36.1K | 0.07% | 0.00% | Sep 2026 |
Top institutions holding ARTV.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| RA Capital Management, LLC | 18.0M | 36.73% | +82.23% | Jun 2026 |
| Viking Global Investors LP | 2.60M | 5.33% | 0.00% | Jun 2026 |
| Blackstone Inc | 2.40M | 4.92% | 0.00% | Jun 2026 |
| 5AM Venture Management, LLC | 2.35M | 4.81% | 0.00% | Jun 2026 |
| VR Adviser, LLC | 2.04M | 4.18% | +26.97% | Jun 2026 |
| Franklin Templeton Inc | 2.00M | 4.09% | +283.84% | Jun 2026 |
| Caligan Partners LP | 1.74M | 3.55% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 982K | 2.01% | +372.74% | Jun 2026 |
| Samsara BioCapital, LLC | 955K | 1.95% | 0.00% | Jun 2026 |
| Blue Owl Capital Holdings LP | 875K | 1.79% | 0.00% | Jun 2026 |
| Propel Bio Management LLC | 696K | 1.42% | +375.81% | Jun 2026 |
| BlackRock Inc | 695K | 1.42% | +225.57% | Jun 2026 |
| Citadel Advisors Llc | 609K | 1.25% | +3,739.80% | Jun 2026 |
| Nantahala Capital Management, LLC | 600K | 1.23% | 0.00% | Jun 2026 |
| SILVERARC CAPITAL MANAGEMENT, LLC | 525K | 1.07% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 354K | 0.72% | +247.95% | Jun 2026 |
| BOOTHBAY FUND MANAGEMENT, LLC | 314K | 0.64% | 0.00% | Jun 2026 |
| Revelation Capital Management, LLC | 299K | 0.61% | 0.00% | Jun 2026 |
| Alyeska Investment Group, L.P. | 274K | 0.56% | +173.62% | Jun 2026 |
| Longwood Capital Partners LLC | 260K | 0.53% | 0.00% | Jun 2026 |
Artiva Biotherapeutics, Inc. Common Stock company profile
- Company name
- Artiva Biotherapeutics, Inc. Common Stock
- Ticker
- ARTV.US
- Exchange
- USA Stocks
- Listed since
- Jul 19, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 134
- Fiscal year end
- December
- Address
- 5505 Morehouse Drive, San Diego, CA, United States, 92121
- Phone
- 858 267 4467
- Website
- artivabio.com
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Artiva Biotherapeutics, Inc. Common Stock management
10- Dr. Fred Aslan M.D.CEO, Principal Financial & Accounting Officer and Director · born 1975
- Dr. Gines Diego Miralles M.D.President and Head of Research & Development · born 1962
- Ms. Jennifer Kinsbruner Bush Esq., J.D.Chief Operating Officer · born 1975
- Mr. Christopher P. HoranChief Technical Operations Officer · born 1967
- Dr. Peter Flynn Ph.D.Co-Founder & Strategic Advisor · born 1974
- Dr. Nicholas Veomett Ph.D.Vice President of Corporate Development
- Dr. Heather Raymon Ph.D.Senior Vice President of Research & Early Development · born 1965
- Dr. David Moriarty Ph.D.Senior Vice President of Clinical Operations
- Mr. Benjamin DeweesSenior Vice President of Regulatory Affairs
- Mr. Feng XuSenior Vice President of Biometrics